"Antisickling Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
| Descriptor ID |
D000986
|
| MeSH Number(s) |
D27.505.954.502.135
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antisickling Agents".
Below are MeSH descriptors whose meaning is more specific than "Antisickling Agents".
This graph shows the total number of publications written about "Antisickling Agents" by people in this website by year, and whether "Antisickling Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antisickling Agents" by people in Profiles.
-
Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. Am J Hematol. 2021 11 01; 96(11):1396-1406.
-
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. Br J Haematol. 2021 11; 195(4):612-620.
-
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2020 04 06; 4:CD012389.
-
Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children. Pediatrics. 2019 07; 144(1).
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
-
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2017 05 13; 5:CD012389.
-
Sickle cell disease. Lancet. 2017 07 15; 390(10091):311-323.
-
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13; 387(10019):661-670.
-
Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation. Blood Cells Mol Dis. 2015 Feb; 54(2):155-9.
-
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2014 Jul; 89(7):709-13.